melperone

Also known as FG-5111

Melperone (Bunil (PT), Buronil (AT, BE, CZ, DK, FI†, NL†, NO†, SE), Eunerpan (DE)) is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It first entered clinical use in 1960s.

Key facts

Drug.verifiedrevid: 447616990
Drug.IUPAC_name: 1-(4-fluorophenyl)-4-(4-methylpiperidin-1-yl)butan-1-one
Drug.image: Melperone.svg
Drug.image_class: skin-invert-image
Drug.alt: Skeletal formula of melperone
Drug.width: 250
Drug.image2: Melperone 3D ball.png
Drug.image_class2: bg-transparent
Drug.alt2: Space-filling model of the melperone molecule
Drug.width2: 250
Drug.tradename: Buronil
Drug.legal_status: Rx-only
Drug.routes_of_administration: Oral, intramuscular injection
Drug.bioavailability: 87% (IM), 54% (Oral via syrup), 65% (Oral, tablet)
Drug.protein_bound: 50%
Drug.metabolism: Hepatic
Drug.elimination_half life: 3–4 hours (oral)6 hours (IM)
Drug.excretion: Renal (70% as metabolites, 5.5–10.4% as unchanged drug)

via Wikipedia infobox

Research

193 papers

Interpretation of melperone intoxication: post-mortem concentration distribution and interpretation of intoxication data.Drug metabolism and personalized therapy · 2021
Zuclopenthixol, melperone and haloperidol/levomepromazine in the elderly. Meta-analysis of two double-blind trials at 15 nursing homes in Norway.Current medical research and opinion · 1992
Melperone in the treatment of neuroleptic-resistant schizophrenia.Psychiatry research · 2001
Melperone in the treatment of schizophrenia.Acta psychiatrica Scandinavica. Supplementum · 1989
Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics.Human psychopharmacology · 2009

via PubMed

Wikidata facts

Mass: 263.168543

Show 3 more facts

chemical formula: C₁₆H₂₂FNO
canonical SMILES: CC1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F
Commons category: Melperone

Sources (4)

via Wikidata · CC0

~4 min read

Article

8 sections

Contents

Marketing and indications
Adverse effects
Interactions
Pharmacology
Synthesis
See also
References
External links

==Marketing and indications== It has been tried in treatment-resistant cases of schizophrenia with some (albeit limited) success. It has also been reported effective in the treatment of L-DOPA and other forms of psychosis in Parkinson's disease (although a multicentre, double-blind, placebo-controlled study conducted in 2012 failed to support these findings). It is also known to possess anxiolytic properties. It is marketed in the following countries: Austria Czech Republic Denmark Estonia Finland Germany Iceland Lithuania Latvia Portugal Sweden